Iantrek

Iantrek is a medical technology company which specializes in the bio-interventional ophthalmic surgery (BIOS). From its funding announcement.

$30M GrowthRaised 6 months agoNYC, USAHealthcare & MedtechUSA

In their own words

What Iantrek says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "medical technology company which specializes in the bio-interventional ophthalmic surgery (BIOS)". Source

Why now

Where Iantrek is today

Iantrek announced a funding round of $30M on 29 April 2026.

Latest round
Growth
Amount
$30M
Announced
29 April 2026
Headquarters
NYC, USA
Sector
Healthcare & Medtech
Investors
Not stated
Also participating
Not stated
Relevant leadership
Not stated

Momentum AfterRaise intelligence

AfterRaise Score

50
Steady growth
0 funding signals in the last 90 days
Funding recency
18/40
announced within the last 6 months
Round scale
16/25
round size relative to the market
Funding stage
16/20
Growth
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 29 April 2026
    $30M Growth
    Investors not stated in the announcement.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Accelerated hiring across functions
  • Operational scale
  • Market consolidation

Opportunities this could create

  • Clinical evidence
  • Regulatory affairs
  • Reimbursement and market access
  • Hospital procurement experience
  • Quality systems

Based on the Healthcare & Medtech sector and a Growth round. Not a statement of fact.

Early momentum1 connected signal
  • 29 April 2026$30M Growth announced

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Iantrek is open to

Not yet specified

Iantrek has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Iantrek

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Iantrek?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: your website, what the round is for, in your words, the roles and projects you have open and who leads the team. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Healthcare & Medtech companies

See the sector